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Introduction
This first Advancing in Idiopathic pulmonary fibrosis
Research (AIR) meeting took place in Berlin, on the 4th
and 5th of November 2011, bringing leading experts in the
field of Idiopathic Pulmonary Fibrosis (IPF) and European
clinicians together to share knowledge on recent advances
and practical experience in the management of this devas-
tating disease.
It is widely recognised that although IPF is a rare
fibrosing lung disease it is associated with a tremendous
burden. The estimated median survival of patients with
IPF is 2–5 years following diagnosis, and the mortality
rate is greater than that associated with numerous malig-
nancies [1,2].
This has presented significant challenges in patient man-
agement and until recently there were no pharmacological
treatments approved for patients with IPF in Europe.
The timing of this meeting was therefore particularly
relevant as there were a number of important advances
and new findings during 2011, which included the publica-
tion of the updated guidelines from the ATS/ERS/JRS/
ALAT Committee and the approval of pirfenidone for the
treatment of mild-to-moderate IPF in Europe [3,4].
In addition, a press release from the National Institutes
of Health reported that one arm of an ongoing trial,
PANTHER-IPF, had been stopped because patients with
IPF receiving a currently used triple-drug therapy consist-
ing of prednisone, azathioprine, and N-acetylcysteine
(NAC) had worse outcomes than those who received
matching placebo. The interim results from PANTHER-
IPF have since been published [5].
This supplement to Respiratory Research reported the
proceedings from this first European IPF meeting, with
key articles selected by the AIR Scientific Committee,
which were considered essential reading for all clinicians
managing patients with IPF in Europe.
Articles in this supplement included a review of the
recently updated ATS/ERS/JRS ALAT diagnostic criteria
by Professor Athol Wells, and discussion on how these
can facilitate early diagnosis of IPF. It also considered
issues that may remain unclear despite the updated gui-
dance. Linked to the diagnosis of IPF, Nicola Sverzellati
gave a master class on HRCT imaging and practical
requirements for optimising CT scanning techniques.
Presentations then focused on the management of IPF.
Professor Luca Richeldi discussed the Cochrane Colla-
boration approach to analysing clinical trial data and the
findings of Cochrane meta-analyses that have been per-
formed to determine the effect of treatments used in the
management of IPF. This was followed by Professor Vin-
cent Cottin, who summarised the outcomes from prior
clinical trials in IPF and the recently published Phase III
studies of pirfenidone that led to its approval in Europe.
Following these updates, Professor Jürgen Behr and Luca
Richeldi discussed how these data can be interpreted in
light of the updated recommendations of the ATS/ERS/
JRS/ALAT Committee regarding treatment of IPF. Profes-
sor Carlo Albera outlined the implications of the press
release from the NIH regarding the PANTHER-IPF study.
Hopefully the selected proceedings from this meeting
will provide IPF clinicians with new insights and support
in the management of their patients. The intention is for
the AIR meeting to become a fixed date in the calendar
for respiratory physicians and researchers dedicated to
improving knowledge and bringing new hope for IPF
patients.
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